RegulatoryCNBC-TV18
Natco Pharma gets seven USFDA observations at Hyderabad plant
GreyOak summary
Natco Pharma received seven observations from the US FDA following an inspection of its formulations manufacturing facility in Kothur, Hyderabad, conducted between November 12 and November 20, 2026. The observations were issued in Form 483, which the company believes are procedural in nature. Natco Pharma stated it is confident of addressing these observations comprehensively within the stipulated timelines.
What it affects
- Natco PharmaNATCOPHARMNegative -33
Received seven USFDA observations at Hyderabad plant.Rolling sentiment Negative -35
Source
Reported by CNBC-TV18
- Business Today
- BusinessLine
- Economic Times
- Economic Times
- Economic Times
- CNBC-TV18
More Natco Pharma news
- Natco Pharma receives EIR from US FDA for Visakhapatnam plantCNBC-TV18 · Company update ·
- Buy Natco Pharma: target of Rs 1065: ICICI SecuritiesMoneycontrol · Company update ·
- Natco Pharma shares rally 9% despite weak Q2 resultsNDTV Profit · Results ·